EULAR has called upon the European Union to develop new therapeutic strategies to reduce the burden of rheumatic and musculoskeletal diseases and disease-related comorbidities. The announcement comes after recent studies have shown that rheumatic and musculoskeletal diseases may be associated with an increased risk of lethal comorbidities such as mental health disorders, gastrointestinal diseases, lung diseases, cardiovascular diseases, and cancers. Consequently, treatments for these comorbidities are often prioritized over treatments for rheumatic and musculoskeletal diseases—which can lead to worse pain, inflammation, mental health, and overall quality of life among affected patients. Researchers have found that patients with rheumatic and musculoskeletal diseases may have a 63% increased risk of experiencing a heart attack and that 20% of cancers in this population may be caused by inflammation. However, EULAR highlighted that anti-inflammatory agents, psychological rehabilitation, and greater access to rheumatologic care can help these patients reduce their risk of lethal comorbidities. EULAR advised the European Union to focus on preventive measures, quality care standards, rehabilitation, social policies, and research initiatives to improve outcomes in this patient population.
June 19, 2023